Counsyl believes its data is robust, while Natera has called the methodology and conclusions "gratuitously wrong." Both published opposing response letters this week.
At last week's ESHG annual meeting, three quality assessment providers discussed best practice guidelines and results from a pilot NIPT quality assessment scheme.
The UK-based firm said that it "will vigorously pursue all options to recover the debt or equivalent assets."
The firm plans to include seven subchromosomal alterations to its NIPT by the end of March and wants to expand into the liquid biopsy market.
The investment bank set a price target of $18.00 for shares of the molecular diagnostics company.
Natera alleges that Bio-Reference broke a contract by promoting a NIPS test based on Illumina technology over Panorama.
The new BGISEQ-50, a smaller version of the BGISEQ-500, will have research and clinical applications, and BGI plans to register it with the CFDA, too.
By offering NIPT as a secondary screening test, the UK hopes to reduce the number of invasive diagnostic tests and associated miscarriages.
Several academic and commercial groups are developing clinical cell-based noninvasive prenatal tests, which could eventually compete with current cell-free NIPTs.
The court ordered the molecular diagnostic company to stop offering the Fetalis test it started offering in Germany this summer, which is based on Ariosa's technology.
Gene drives might run into biological resistance, the Economist reports.
Forensic experts exhumed painter Salvador Dalí's body to collect DNA for a paternity test, CBS News reports.
Yale Environment 360 writes that synthetic and conservation biologists aren't always on the same wavelength, but they are trying to reach an understanding.
In Science this week: full CRISPR locus integration complex structure, and more.